First human trial of partial cellular reprogramming begins in Boston

A patient has received the first dose of an experimental gene therapy designed to reverse cellular aging, marking a pivotal shift from laboratory models to clinical reality. Boston-based Life Biosciences is testing the treatment, ER-100, on individuals suffering from glaucoma and age-related optic nerve damage.

The therapy functions by delivering modified reprogramming factors directly into the eye, aiming to restore youthful gene expression patterns without stripping cells of their original identity. The procedure relies on a precise biological mechanism: a single injection followed by a course of antibiotics that serves as a chemical trigger to activate the therapeutic genes. By focusing on the eye—a region relatively isolated from the rest of the body—researchers hope to mitigate systemic risks while evaluating the treatment’s safety and efficacy in fewer than 20 participants across Boston, New York, Los Angeles, and Charleston.

This research builds upon the Information Theory of Aging, which posits that cells lose access to vital instructions over time. While previous successes in mice and monkeys demonstrated that partial reprogramming could regrow optic nerve connections, the human application remains high-risk. The primary concern is tumorigenesis; if the reprogramming factors remain active too long, cells could lose their specialized function and begin to divide uncontrollably. Consequently, this Phase 1 trial serves as a narrow test of safety, determining whether the epigenetic restoration used in the lab can safely translate to patients without inducing tumor growth. If successful, the platform could eventually pivot to address broader conditions, including Alzheimer’s and heart disease.